However, other studies reported PD-L1 positivity in aggressive primary prostate carcinomas, also with a prognostic significance since it has been correlated to biochemical recurrence [89] and high expression in both preclinical and clinical models of enzalutamide-resistant prostate cancer [90]. Here, CD274 is linked to prostate cancer.